Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus

Experimental and Clinical Endocrinology and Diabetes

Volumn 108, Issue 3, 2000, Pages 151-163

  Füchtenbusch, Martin ^a   Standl, Eberhard ^a   Schatz, Helmut ^b  

^a Klinikum Schwabing   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Combination therapy; Glinides; Glitazones; Glycaemic control; Hypoglycemia; Insulin resistance; Insulin secretagogues; Insulin sensitizer; Nateglinide; Pioglitazone; Prandial glucose regulation; Repaglinide; Responder; Rosiglitazone

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; NATEGLINIDE; PIOGLITAZONE; POTASSIUM CHANNEL BLOCKING AGENT; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; THIAZOLIDINE DERIVATIVE; TROGLITAZONE;

ADULT; AGED; BLOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EDEMA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIA; LIVER FAILURE; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

CARBAMATES; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; PHENYLALANINE; PIPERIDINES; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0034024914     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-7737     Document Type: Review

References (50)

1. Beebe KL: Rosiglitazone is effective and well tolerated in patients >65 years with type 2 diabetes. Diabetologia 42 (Suppl 1) A227: 854, 1999
2. Bretzel RG, Voigt K, Schatz H: The United Kingdom Prospective Diabetes Study (UKPDS) Implications for the Pharmacotherapy of Type 2 Diabetes Mellitus. Exp Clin Endocrinol Diabetes 106: 369-372, 1998
3. Chuang LM, Juang JH, Wu HP, Chiang YD, Li KL, Jorgensen LN, Tai TY: Clinical efficacy and safety of NovoNorm® in the treatment of Chinese Type 2 diabetes in Taiwan. Diabetologia 42 (Suppl 1) A241: 908, 1999
4. Cranmer H, Jones NP, Patwrdhan R: Rosiglitazone is effective in both obese and non-obese patients with type 2 diabetes. Diabetologia 42 (Suppl 1) A228: 856, 1999
5. Damsbo P, Clauson P, Marbury TC, Windfeld K: A double-blind randomized comparison of meal-related glycemic control by Repaglinide and Glyburide in well-controlled type 2 diabetic patients. Diabetes Care 22: 789-794, 1999
6. Dejgaard A, Madsbad S, Kilhovd B, Lager I, Mustajoki P: Repaglinide compared to Glipizide in the treatment of type 2 diabetic patients. Diabetologia 41 (Suppl 1) A236: 914, 1998
7. Egan J, Rubin C, Mathisen A Pioglitazone 027 Study group: Combination therapy with Pioglitazone and Metformin in patients with Type 2 diabetes. Diabetes 48 (Suppl 1) A117: 0504, 1999
8. European NIDDM Policy group 1998-1999: A desktop guide to type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 107: 390-420, 1999
9. Fonseca V, Biswas N, Salzmann A: Rosiglitazone in combination with Metformin effectively reduces hyperglycemia in patients with Type 2 diabetes. Diabetologia 42 (Suppl 1) A230: 864, 1999
10. Frandsen KB, Moses R, Gomis R, Clauson P: Efficacy and safety study of Repaglinide, a flexible prandial glucose regulator, in type 2 diabetes patients. Diabetologia 42 (Suppl 1) A242: 910, 1999
11. Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, Shymko R, Carr RD: Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 47: 345-351, 1998
12. Glatt M, Schatz H: The influence of an acyl-amino-alcyl-benzoic acid (HB 699) on biosynthesis and secretion of insulin in isolated rat islets of Langerhans. Diabe & Metabolisme (Paris) 7: 105-108, 1981
13. Goldberg RB, Einhorn D, Lucas CP, Rendell MS, Damsbo P, Huang W-C, Strange P, Brodows RG: A randomized placebo-controlled trial of Repaglinide in the treatment of type 2 diabetes. Diabetes Care 21: 1897-1998, 1998
14. Goldstein B, Salzmann A: Rosiglitazone in poorly controlled type 2 diabetes patients. Diabetologia 42 (Suppl 1) A229: 861, 1999
15. Gomis R, Jones NP, Vallance SE, Patwardhan R: Low-dose Rosiglitazone enhances glycemic control when combined with sulphonylureas in Type 2 diabetes. Diabetologia 42 (Suppl 1) A227: 851, 1999
16. Grunberger G, Weston WM, Patwardhan R, Rappaport EB: Rosiglitazone once or twice daily improves glycemic control in patients with type 2 diabetes. Diabetologia 42 (Suppl 1) A4: 8, 1999
17. Hirschberg Y, McLeod J, Gareffa S, Spratt D: Pharmacodynamics and dose response of nateglinide in type 2 diabetics. Diabetes 48 (Suppl 1) A100: 0430, 1999
18. Jones NP, Charbonnel B, Lönnquist F, Owen S, Patwardhan R: Rosiglitazone reduces plasma insulin and ist precursors while decreasing glycemia in type 2 diabetes. Diabetologia 42 (Suppl 1) A229: 859, 1999
19. Kalbag J, Hirschberg Y, McLeod J, Gareffa S, Lasseter K: Comparison of mealtime glucose regulation by Nateglinide and Repaglinide in Healthy subjects. Diabetes 48 (Suppl 1) A167: 0456, 1999
20. Kreider M, Miller E, Patel J: Rosiglitazone (RSG) is safe and well tolerized as montherapy or combination therapy in patietns with type 2 diabetes mellitus. Diabetes 48 (Suppl 1) A117: 0506, 1999
21. Landin-Olsson M, Brogard M, Erikkson J, Rasmussen M, Clauson P: The efficacy of Repaglinide administered in Combination with bestime NPH-insulin in patients with type 2 diabetes. A randomized, semi-blinded, parallel Group, Multicenter Trial. Diabetes 48 (Suppl 1) A117: 0503, 1999
22. Lebovitz HE, Patel J, Dole J, Patwardhan R: Rosiglitazone (BRL 49653) Monotherapy has significant Glucose effect in type 2 diabetic patients. Diabetologia 41 (Suppl 1) A238: 922, 1998
23. Lönnqvist F, Charbonnel B, Jones NP, Abel MG, Patwardhan R: Rosiglitazone is superior to Glibenclamide in reducing fasting plasma glucose in Type 2 diabetic patients. Diabetologia 42 (Suppl 1) A231: 869, 1999
24. Mathisen A, Geerlof J, Houser V on behalf of the Pioglitazone 026 Study group: The effect of Pioglitazone on glucose control and lipid profile in patients with type 2 diabetes. Diabetologia 8 (Suppl 1) A227: 853, 1999
25. Matthews DR, Bakst A, Weston WM, Hemyari P: Rosiglitazone decreases insulin resistance and improves beta-cell function in patients with type 2 diabetes. Diabetologia 42 (Suppl 1) A228: 858, 1999
26. Matthews DR, Hosker JP, Rudensky AS, Naylor BA, Trencher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diahetologia 28: 312-419, 1985
27. Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, Donelly T, Moffitt P, Hopkins H: Effect of Repaglinide addition to Metformin monotherapy on glycemic control in patients with Type 2 Diabetes. Diabetes Care 22: 119-124, 1999
28. Nathan DM: Some answers, more controversy, from UKPDS. Lancet 352:832-833, 1998
29. Nolan JJ, Jones NP, Patwardhan R, Deacon LF: Once-daily Rosiglitazone is effective in the treatment of type 2 diabetes mellitus. Diabetes 48 (Suppl 1) A111: 0478, 1999
30. Patel J, Anderson RJ, Rappaport EB: Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomised, placebo-controlled study. Diabetes, Obesity and Metabolism 1: 165-172, 1999
31. Polonsky KS, Given BD, Hirsch L, Shapiro ET, Tillil H, Beebe C, Galloway JA, Frank BH, Karrison T, Van Gouter E: Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest 81: 435-441, 1988
32. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, Frank BH, Galloway JA, Van Gouter E: Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 318: 1231-1239, 1988
33. Polonsky KS: Evolution of β-cell dysfunction in impaired glucose tolerance. Exp Clin Endocrinol Diabetes 107 (Suppl 4): 124-127, 1999
34. Raskin P, Dole JF, Rappaport EB: Rosiglitazone (RSG) improves glycemic control in poorly controlled, insulin-treated Type 2 Diabetes (T2D). Diabetes 48 (Suppl 1) A94: 0404, 1999
35. Raskin P, Kennedy F, Woo V, Rajeev J, Boss AH: A multicenter, randomized study of the therapeutic effect of Repaglinide combined with troglitazone in subjects with type 2 diabetes. Diabetes 48 (Suppl 1) A107: 0463, 1999
36. Rubin C, Egan J, Schneider R Pioglitazone 014 Study group: Combination therapy with Pioglitazone and Insulin in Patients with Type 2 Diabetes. Diabetes 48 (Suppl 1) A110: 0474, 1999
37. Salzman A: Rosiglitazone is not associated with hepatotoxicity. Diabetologia 42 (Suppl 1) A3: 2, 1999
38. Schatz H: Preclinical and clinical studies on safety and tolerability of repaglinide. Exp Clin Endocrinol Diabetes 107 (Suppl 4): S144-S148, 1999
39. Schneider R, Egan J, Houser V Pioglitazone 010 Study Group: Combination therapy with Pioglitazone and Sulphonylurea in Patients with Type 2 diabetes. Diabetes 48 (Suppl 1) A106: 0458, 1999
40. Schneider R, Lessem J, Lekich R: Pioglitazone is efeective in the treatment of patients with Type 2 diabetes. Diabetes 48 (Suppl 1) A109: 0469, 1999
41. Singer DE, Nathan DM, Anderson KM, Wilson PWF, Evans JC: Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 41: 202-208, 1992
42. Spiegelman BM: PPAR-γ: Adipogenic regulator and thiazolidinedion receptor. Diabetes 47(4): 507-514, 1998
43. Tabona MV, Weill S, Patwardhan R: Rosiglitazone given once or twice daily is effective first-line treatment for type 2 Diabetes mellitus. Diabelologia 42 (Suppl 1) A231: 867, 1999
44. UKPDS Group: Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-865, 1998
45. UKPDS Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853, 1998
46. Uusitupa MIJ, Niskanen LK: Hyperglycemia and cardiovascular risk in NIDDM. Diabetes Care 18: 884-885, 1995
47. Watkins PB, Whitcomb RW: Hepatic dysfunction associated with troglitazone. N Engl J Med 338: 916-917, 1998
48. Whitcomb RW, Saltiel AR: Thiazolidinediones. Expert Opin Invest Drug 4(12): 1299-1309, 1995
49. Wolffenbuttel BHR, Landgraf R on behalf of the Dutch and German Repaglinide Study group: A 1-year mullicenter randomized double-blind comparison of repaglinide and Glybunde fir the treatment of Type 2 diabetes. Diabetes Care 22: 463-468, 1999
50. Zimmet PZ: Diabetes epidemiology as a tool to trigger diabetes research and care. Diabetologia 42: 499-518, 1999